179 related articles for article (PubMed ID: 35228392)
1. ETV6 Regulates Hemin-Induced Erythroid Differentiation of K562 Cells through Mediating the Raf/MEK/ERK Pathway.
Li Z; Sun MZ; Lv X; Guo C; Liu S
Biol Pharm Bull; 2022; 45(3):250-259. PubMed ID: 35228392
[TBL] [Abstract][Full Text] [Related]
2. CRKL but not CRKII contributes to hemin-induced erythroid differentiation of CML.
Guo C; Lv X; Zhang Q; Yi L; Ren Y; Li Z; Yan J; Zheng S; Sun MZ; Liu S
J Cell Mol Med; 2024 May; 28(9):e18308. PubMed ID: 38683131
[TBL] [Abstract][Full Text] [Related]
3. ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent.
Woessmann W; Zwanzger D; Borkhardt A
Cell Biol Int; 2004; 28(5):403-10. PubMed ID: 15193284
[TBL] [Abstract][Full Text] [Related]
4. Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells.
Sumi K; Tago K; Nakazawa Y; Takahashi K; Ohe T; Mashino T; Funakoshi-Tago M
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054935
[TBL] [Abstract][Full Text] [Related]
5. Role of ERK activation in growth and erythroid differentiation of K562 cells.
Woessmann W; Mivechi NF
Exp Cell Res; 2001 Apr; 264(2):193-200. PubMed ID: 11262176
[TBL] [Abstract][Full Text] [Related]
6. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
7. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
[TBL] [Abstract][Full Text] [Related]
8. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.
Wang J; Zhao Y; Kauss MA; Spindel S; Lian H
Eur J Cell Biol; 2009 Feb; 88(2):103-15. PubMed ID: 19058874
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of transglutaminase 2 accelerates the erythroid differentiation of human chronic myelogenous leukemia K562 cell line through PI3K/Akt signaling pathway.
Kang SK; Lee JY; Chung TW; Kim CH
FEBS Lett; 2004 Nov; 577(3):361-6. PubMed ID: 15556610
[TBL] [Abstract][Full Text] [Related]
10. Spred2 modulates the erythroid differentiation induced by imatinib in chronic myeloid leukemia cells.
Yang Y; Liu X; Xiao F; Xue S; Xu Q; Yin Y; Sun H; Xu J; Wang H; Zhang Q; Wang H; Wang L
PLoS One; 2015; 10(2):e0117573. PubMed ID: 25688862
[TBL] [Abstract][Full Text] [Related]
11. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
[TBL] [Abstract][Full Text] [Related]
12. Role of G proteins and ERK activation in hemin-induced erythroid differentiation of K562 cells.
Kucukkaya B; Arslan DO; Kan B
Life Sci; 2006 Feb; 78(11):1217-24. PubMed ID: 16216279
[TBL] [Abstract][Full Text] [Related]
13. ALDH6A1 weakens the progression of colon cancer via modulating the RAS/RAF/MEK/ERK pathway in cancer cell lines.
Li X; Wang N; Wu Y; Liu Y; Wang R
Gene; 2022 Oct; 842():146757. PubMed ID: 35907565
[TBL] [Abstract][Full Text] [Related]
14. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
15. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
[TBL] [Abstract][Full Text] [Related]
16. Effects of THAP11 on erythroid differentiation and megakaryocytic differentiation of K562 cells.
Kong XZ; Yin RH; Ning HM; Zheng WW; Dong XM; Yang Y; Xu FF; Li JJ; Zhan YQ; Yu M; Ge CH; Zhang JH; Chen H; Li CY; Yang XM
PLoS One; 2014; 9(3):e91557. PubMed ID: 24637716
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors.
Zhang J; Lodish HF
Blood; 2004 Sep; 104(6):1679-87. PubMed ID: 15166036
[TBL] [Abstract][Full Text] [Related]
18. CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Huang SY; Liu YH; Chen YJ; Yeh YY; Huang HM
J Cell Physiol; 2018 Sep; 233(9):7467-7479. PubMed ID: 29663362
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
Kawano T; Horiguchi-Yamada J; Iwase S; Furukawa Y; Kano Y; Yamada H
Mol Cell Biochem; 2004 Mar; 258(1-2):25-33. PubMed ID: 15030167
[TBL] [Abstract][Full Text] [Related]
20. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
Ma L; Shan Y; Bai R; Xue L; Eide CA; Ou J; Zhu LJ; Hutchinson L; Cerny J; Khoury HJ; Sheng Z; Druker BJ; Li S; Green MR
Sci Transl Med; 2014 Sep; 6(252):252ra121. PubMed ID: 25186176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
